Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

ABSTRACT:

Background

There are limited data on the pharmacogenetics and pharmacokinetics of the CNS penetration of efavirenz.

Objectives

We investigated genetic polymorphisms associated with CSF concentrations of efavirenz and its metabolites and explored the relationships with neurocognitive performance.

Methods

We included 47 HIV-infected South African black adults with and without HIV-associated neurocognitive disorder on efavirenz/tenofovir/emtricitabine and collected paired plasma-CSF samples. We considered 2049 SNPs, including SNPs known to affect plasma efavirenz exposure, from potentially relevant genes (ABCC5, ABCG2, ABCB1, SLCO2B1, SCLO1A2, ABCC4, CYP2B6 and CYP2A6) and 880 met a linkage disequilibrium (LD)-pruning threshold.

Results

We identified 9 slow, 21 in

SUBMITTER: Decloedt EH 

PROVIDER: S-EPMC6376850 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature